Penile Implant (Penile Prosthesis) — Treatment Guide for Erectile Dysfunction — Cost, Top Hospitals & Success Rates | MyMedicPlus

A penile implant (penile prosthesis) is a surgically implanted device designed to restore erectile function in men with erectile dysfunction (ED) that has not responded to conservative treatments including oral phosphodiesterase type-5 inhibitors (PDE5i — sildenafil, tadalafil, vardenafil), intraurethral alprostadil (MUSE), or penile injection therapy (intracavernosal alprostadil). Penile prosthesis implantation represents the definitive surgical management of ED and is considered the "gold standard" endpoint of the ED treatment pathway when pharmacological therapy has failed, is contraindicated, or is declined by the patient.

The procedure involves the surgical placement of paired cylinders within the two corpora cavernosa — the erectile chambers that run the length of the penis — through either a penoscrotal or infrapubic incision. Depending on the device type chosen, a fluid pump is placed in the scrotum and a fluid reservoir is placed either in the space of Retzius (behind the pubic bone) or trans-submuscularly to complete a three-piece inflatable system that mimics natural erection and flaccidity.

Modern penile prostheses represent an extraordinary technical achievement in urological surgery. The three-piece inflatable prosthesis — introduced in the 1970s and refined continuously since — achieves approximately 90–95% patient and partner satisfaction at five years, making it one of the highest-satisfaction surgical interventions in urology. Antibiotic-impregnated device coatings introduced in the late 1990s have reduced infection rates from approximately 3–5% to 1–2% in standard-risk patients, further improving the long-term implant survival profile.

Penile prosthesis surgery is indicated for erectile dysfunction from any aetiology that has proven refractory to conservative management. The following conditions most commonly lead to penile implant surgery:

• Vasculogenic erectile dysfunction: The most common category, including ED from atherosclerosis, hypertension, dyslipidaemia, and diabetes mellitus. Diabetic men with autonomic neuropathy and microvascular disease frequently develop severe vasculogenic ED that responds poorly to oral PDE5 inhibitors, making them among the most common candidates for prosthetic surgery.
• Post-radical prostatectomy ED: Surgical removal of the prostate for prostate cancer (radical prostatectomy) causes cavernous nerve injury in virtually all patients, leading to severe ED in the majority — even with nerve-sparing technique. Recovery of natural erectile function post-prostatectomy is unpredictable and often incomplete. Many post-prostatectomy patients who fail pharmacological penile rehabilitation progress to prosthetic implantation, often within 2–3 years of cancer surgery.
• Peyronie's Disease (PD): Fibrous plaque formation within the tunica albuginea causes penile curvature, shortening, and in advanced cases, ED from inadequate rigidity. Penile prosthesis implantation addresses both the curvature and ED simultaneously. Intraoperative manual modelling over the inflated cylinders can straighten the penis without additional grafting in the majority of cases. This population has a lower natural erection capacity to preserve, making early transition to prosthetic surgery a rational choice.
• Priapism-related ED: Ischaemic priapism (prolonged erection exceeding 36–48 hours) causes irreversible cavernosal smooth muscle ischaemia and fibrosis, resulting in permanent ED. Early prosthesis placement (within days to weeks of priapism episode) has been advocated by some authorities before fibrosis makes standard cylinder placement technically difficult.
• Neurogenic ED: Spinal cord injury, multiple sclerosis, and pelvic nerve injury from colorectal or bladder surgery cause neurogenic ED that is typically refractory to oral agents. Prosthetic surgery provides reliable, on-demand erections independent of the neurological deficit.
• Psychogenic ED refractory to therapy: A minority of men with severe performance anxiety or psychogenic ED unresponsive to combination pharmacological and psychosexual therapy may choose prosthetic surgery, though careful psychological evaluation before proceeding is essential to optimise outcomes.

Candidacy for penile prosthesis implantation is determined through a structured urological and psychosexual assessment. The following criteria and contraindications guide patient selection:

• Failed conservative therapy: Current AUA guidelines recommend that penile prosthesis surgery should generally be offered only after failure or intolerance of oral PDE5i therapy (typically both sildenafil and tadalafil at maximally effective doses), intraurethral alprostadil, and intracavernosal injection therapy. Patients who cannot self-inject or are needle-phobic may be considered for prosthesis after documented PDE5i failure alone.
• Medical fitness for surgery and anaesthesia: Penile prosthesis implantation is performed under general or regional (spinal/epidural) anaesthesia. Patients must be medically optimised — particularly with respect to glycaemic control in diabetics (HbA1c below 8.0% recommended to minimise infection risk), and management of anticoagulant therapy. Active urinary tract infection or genital skin infection is an absolute contraindication to elective implantation.
• Psychological readiness: Thorough informed consent must address realistic expectations regarding post-operative penile length (prostheses typically result in a perceived reduction in flaccid penile size compared with the patient's pre-ED erection), the mechanical nature of the erection achieved, and the permanent, irreversible nature of prosthesis implantation. Placement of a prosthesis destroys the remaining natural erectile tissue, making the procedure irrevocable.
• High-risk patients: Patients with insulin-dependent diabetes, immunosuppression, prior pelvic radiation, or previous prosthesis infection are at significantly elevated risk of implant infection and must be extensively counselled. Some surgeons recommend antibiotic-impregnated or hydrophilic-coated devices as standard in all patients, not only high-risk groups, given the superior infection prevention profile.
• Stable partnership (where applicable): Partner involvement in the pre-operative counselling process is strongly recommended and associated with higher post-operative satisfaction in both the patient and partner. Partner dissatisfaction with the prosthetic erection — which produces neither warmth nor the progressive tumescence of natural erection — can be a source of relationship difficulty if not addressed pre-operatively.

Penile prostheses fall into two principal categories — inflatable and semi-rigid (malleable) — with the choice guided by patient anatomy, comorbidities, manual dexterity, and surgeon expertise:

• 3-Piece Inflatable Prosthesis (IPP) — AMS 700 CX/LGX: The most widely implanted prosthesis type worldwide. The AMS 700 system (Boston Scientific) consists of paired cylinders placed in the corpora cavernosa, a scrotal pump that the patient squeezes to transfer fluid from the reservoir to the cylinders (producing erection), and a fluid reservoir placed in the space of Retzius. The CX cylinder provides girth expansion only (suitable for Peyronie's disease or scarred corpora); the LGX cylinder provides both length and girth expansion. The AMS 700 is coated with InhibiZone — a rifampicin and minocycline antibiotic coating — reducing infection risk to approximately 1–2%.
• 3-Piece Inflatable Prosthesis — Coloplast Titan: The principal competitor device from Coloplast. The Titan features a unique polytetrafluoroethylene (PTFE) cylinder surface coated with hydrophilic polyvinylpyrrolidone (PVP) — an antibiotic-absorbing coating that is loaded with antibiotic solution by the surgical team intraoperatively (typically vancomycin and gentamicin). The Titan Zero Degree pump is considered by many surgeons to be more user-friendly than the AMS pump, with a self-contained lock-out valve. The Titan offers equivalent patient satisfaction and 5-year mechanical survival to the AMS 700.
• Reservoir placement alternatives: Traditional reservoir placement in the space of Retzius is contraindicated in patients with prior pelvic surgery, artificial urinary sphincter placement, or mesh from hernia repair. Trans-submuscular reservoir placement (above the transversalis fascia) or in-situ reservoir placement (within the lower lateral abdomen) are safe alternatives that have equivalent functional outcomes.
• Semi-Rigid (Malleable) Prostheses — Coloplast Genesis / AMS Spectra: Two paired malleable rods are placed in the corpora cavernosa, providing a permanently semi-rigid penis that can be bent downward for concealment. Advantages include simplicity, lower cost, absence of mechanical failure risk, and ease of use for patients with poor manual dexterity (spinal cord injury, severe arthritis). Disadvantages include less natural appearance, potential for concealment difficulty, and higher pressure on corporal tissue. Suitable for elderly or less sexually active patients and for those with severe corporal fibrosis where cylinder inflation may be technically challenging.
• Surgical approaches: The penoscrotal approach (scrotal-penile junction incision) is the most widely used — providing excellent corporal exposure and direct scrotal pump placement. The infrapubic approach (suprapubic incision below the pubic bone) provides direct space-of-Retzius reservoir access but risks injury to dorsal penile neurovascular structures and bladder if not carefully performed. The choice is largely surgeon-preference-dependent; outcomes are equivalent between approaches.

Penile prosthesis implantation offers profound benefits for men with refractory ED and their partners, supported by decades of long-term outcome data:

• Reliable, on-demand erections: Unlike pharmacological therapy — which requires anticipation, a defined time window, and response variability — a penile prosthesis produces a reliable, predictable erection on demand within seconds of pump activation. This restores sexual spontaneity that is consistently cited by patients and partners as one of the most significant quality-of-life benefits.
• Exceptional patient satisfaction: Published long-term data consistently demonstrate patient satisfaction rates of 90–95% at five years for the three-piece inflatable prosthesis — among the highest of any surgical procedure in urology. Partner satisfaction rates of 80–85% are also reported in studies including partner-reported outcomes.
• Simultaneous Peyronie's disease correction: Penile prosthesis implantation combined with intraoperative manual modelling corrects Peyronie's-associated penile curvature in approximately 85% of cases without additional incisions or grafting, providing a two-in-one solution for men affected by both ED and penile deformity.
• Long-term mechanical reliability: Modern inflatable prostheses demonstrate 10-year mechanical survival rates of 80–85% (freedom from mechanical failure requiring revision surgery), reflecting the substantial engineering improvements in cylinder materials and pump design since the first generation devices.
• Preserved penile sensation: Penile prosthesis surgery does not damage the pudendal nerve or its branches responsible for penile sensation and orgasm. Sexual sensation, orgasmic capacity, and ejaculatory function are preserved in the vast majority of patients — the prosthesis provides rigidity only, not sensation.
• Post-cancer rehabilitation: For men with post-prostatectomy ED, the penile prosthesis represents the most reliable and sustainable erection recovery strategy, with satisfaction rates superior to all other ED treatment modalities in this population when pharmacological rehabilitation has failed.

Penile prosthesis implantation is a safe procedure with well-characterised risks that must be discussed comprehensively before surgery:

• Infection: The most feared and consequential complication of penile prosthesis surgery. Device infection rates have been reduced dramatically by antibiotic-impregnated coatings (InhibiZone, Titan hydrophilic coating) to approximately 1–2% in standard-risk patients and 2–5% in high-risk patients (diabetics, immunosuppressed, prior implant). Established prosthesis infection typically requires complete device explantation. The Mulcahy salvage protocol — immediate device explantation followed by copious antibiotic irrigation of the corporal spaces and immediate new device replacement — salvages the implant space in approximately 80% of cases when performed promptly by experienced surgeons.
• Mechanical failure: Cylinder leak, pump failure, tubing kink, or reservoir herniation requiring revision surgery affect approximately 15–20% of devices over 10 years. Mechanical failure rates have declined substantially with modern devices but remain a reality of prosthetic surgery that patients must understand as a long-term risk.
• Perceived penile shortening: The most common source of post-operative dissatisfaction. Men with severe ED, particularly those with long-standing untreated ED, experience corporal tissue atrophy and penile shortening from disuse before surgery. The prosthesis cylinders expand the corpora to their existing maximum but do not lengthen shortened tissue. Extensive pre-operative counselling about this "length concern" is mandatory.
• Erosion: Cylinder or reservoir erosion through the skin or urethra occurs in less than 1–2% of cases, most commonly in patients with corporal fibrosis, diabetes with thin tissue, or neurogenic disease with impaired sensation. Erosion requires device removal and, where possible, reimplantation after healing.
• Haematoma: Scrotal or penoscrotal haematoma occurs in approximately 2–3% of cases and may require surgical evacuation if large. Meticulous haemostasis and adherence to anti-coagulant bridging protocols minimise risk.
• Auto-inflation: Spontaneous partial inflation of a 3-piece IPP without pump activation — caused by high reservoir pressure transmitted to cylinders — affects approximately 2–5% of patients. Repositioning the reservoir or switching to a lockout valve device resolves most cases.
• Anorgasmia or altered ejaculation: Orgasmic dysfunction and altered ejaculatory quality may occur in a minority of patients, particularly those with concurrent neurological injury. These symptoms are related to the underlying neurological condition rather than the prosthesis itself.

Post-operative management of penile prosthesis implantation follows a structured protocol designed to protect the healing wound, prevent infection, and prepare the patient for successful device use:

• Immediate post-operative period: The device is left in the deflated (or semi-inflated for saline devices) position for 4–6 weeks while the tissue planes around the cylinders heal and form the fibrous pseudo-capsule that anchors the device. A penoscrotal or perineal dressing and scrotal elevation are used to minimise oedema. A urethral catheter is typically removed on the first post-operative day.
• Antibiotic prophylaxis: Intravenous antibiotics (aminoglycoside plus vancomycin or appropriate MRSA-active beta-lactam) are administered peri-operatively. Oral antibiotics are continued for 7–10 days post-operatively at many centres, though evidence for post-discharge oral antibiotics is limited. Antibiotic stewardship protocols should guide the choice of agents.
• Device activation and training: At 4–6 weeks post-operatively, the patient returns to the surgeon's office for initial device activation and training. Detailed instruction in pump location and function, inflation technique (typically 8–12 pump compressions for full inflation), deflation (pressing the deflation valve at the base of the pump), and troubleshooting is provided. A nurse specialist or device company representative may assist with training.
• Post-Peyronie's modelling: For patients who underwent concurrent Peyronie's disease modelling, the device is inflated to maximum rigidity and firm bimanual pressure applied to the remaining residual curvature at the 4-week activation visit. This stretches residual plaque and consolidates curvature correction. Up to 3–5 modelling sessions at monthly intervals may be performed.
• Penile rehabilitation and length recovery: Daily device cycling (inflation followed by complete deflation) is recommended from the point of activation to minimise the progressive fibrosis that can further reduce cylinder expandability over time. Penile traction or vacuum erection device use in the pre-operative period is occasionally recommended for patients concerned about length to maximise pre-operative tissue stretch.
• Long-term follow-up: Annual clinical review is recommended to assess device function, patient and partner satisfaction, and early detection of mechanical issues. Patients are instructed to contact their urologist promptly if they notice any change in device function, painful deflation, or signs of infection (erythema, warmth, discharge).

Penile prosthesis implantation is a capital-cost-intensive surgical procedure, primarily due to the device itself. Understanding the full cost landscape is important for patients considering the procedure:

• Device cost: Three-piece inflatable prostheses (AMS 700 or Coloplast Titan) have a manufacturer list price of approximately USD $8,000–$12,000 for the device alone in the USA. Semi-rigid devices (AMS Spectra, Coloplast Genesis) cost approximately USD $2,500–$4,000. International pricing — particularly in India, Turkey, and South Korea — is significantly lower due to different distribution agreements and hospital procurement volumes.
• Total procedural cost in the USA: Including surgeon fees, anaesthesia, surgical facility costs, and device, the total cost of penile prosthesis implantation in the USA ranges from USD $18,000–$35,000 in private practice ambulatory settings, and may be lower in academic or Veterans Affairs hospital settings. Insurance coverage varies significantly by plan and diagnosis documentation.
• Insurance coverage: In the USA, most commercial health insurance plans cover penile prosthesis implantation when medically indicated (documented organic ED refractory to conservative therapy), subject to prior authorisation. Medicare covers the procedure. Medicaid coverage varies by state. Patients should obtain pre-authorisation before scheduling to avoid unexpected out-of-pocket costs.
• Medical tourism considerations: India, Turkey, Thailand, and South Korea offer penile prosthesis implantation — including AMS 700 and Coloplast Titan devices — at total package costs of USD $5,000–$12,000 including device, surgery, anaesthesia, and short hotel stay. Patients pursuing medical tourism should verify that the surgeon has performed a minimum of 50–100 prosthesis implantations annually and that the hospital has documented infection control protocols for prosthetic urological surgery. Post-operative follow-up and management of complications — including the rare but critical event of infection — must be planned with a urologist in the patient's home country before travelling for surgery.
• Revision surgery costs: Mechanical failure or infection requiring device replacement or explantation generates additional surgical costs. Most prosthesis manufacturers offer a limited replacement warranty (typically 5 years for mechanical failure) that substantially reduces device costs at revision in warranted cases.

Before proceeding to surgical implantation, the full spectrum of ED therapies should be offered, discussed, and documented. The following alternatives are appropriate first-line and second-line treatments:

• Oral PDE5 inhibitors (first-line): Sildenafil (Viagra), tadalafil (Cialis — available as daily low-dose or on-demand), vardenafil (Levitra), and avanafil (Stendra) are first-line pharmacological therapy for all forms of organic and psychogenic ED. They are effective in approximately 60–70% of unselected ED patients, with lower response rates in post-radical prostatectomy (30–40%) and severe vascular disease. Failure of two agents at maximal doses with adequate sexual stimulation constitutes pharmacological failure.
• Vacuum Erection Devices (VED): A plastic cylinder placed over the penis generates negative pressure to draw blood into the corpora, with a constriction ring placed at the base to maintain erection during intercourse. VED is effective in 60–80% of men and is particularly useful for penile rehabilitation after radical prostatectomy. Limitations include lack of spontaneity, penile cooling, and partner-reported preference issues.
• Intracavernosal injection therapy (ICI): Self-injection of alprostadil (PGE1), papaverine, or combination vasoactive agents (Trimix: papaverine, phentolamine, alprostadil) directly into the corpus cavernosum produces a pharmacological erection independent of sexual stimulation or nerve function. ICI is highly effective (75–85%) even in post-prostatectomy patients with nerve damage. The principal barriers are needle aversion, priapism risk (prolonged erection requiring emergency treatment), and penile fibrosis with long-term use.
• Intraurethral alprostadil (MUSE): A small alprostadil pellet inserted into the urethra is absorbed into the corpus spongiosum and corpus cavernosum via transurethral absorption. Lower efficacy than ICI (30–50%) but needle-free. Useful as a step-up from oral therapy in men with moderate ED.
• Low-intensity extracorporeal shockwave therapy (LI-ESWT): Applied to the penis to stimulate neovascularisation and cavernosal tissue regeneration. Meta-analyses suggest modest improvement in erectile function scores in men with mild to moderate vasculogenic ED, though long-term durability and optimal treatment protocols are still under investigation. Not currently endorsed as standard therapy by AUA or EAU guidelines for routine ED management.
• Psychosexual therapy: For men with primarily psychogenic ED — performance anxiety, relationship issues, or depression-related sexual dysfunction — individual or couples psychosexual therapy delivered by accredited sex therapists is first-line treatment and should be offered or co-administered alongside pharmacological therapy in all men with ED, regardless of the primary aetiology.